Search company, investor...

AgaPharm

agapharm.com

About AgaPharm

AgaPharm is developing a prescription eye drop for Diabetics. The drug aims to offer a simple, low-cost treatment that can deliver a safe and effective dose to the eye, preventing or slowing down the onset of diabetic blindness and cataract. The company's Research Partner is the Biotechnology Research Institute at the National Research Council of the Government of Canada.

Headquarters Location

Ottawa, Ontario,

Canada

Missing: AgaPharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AgaPharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AgaPharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AgaPharm is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,903 items

AgaPharm Frequently Asked Questions (FAQ)

  • Where is AgaPharm's headquarters?

    AgaPharm's headquarters is located at Ottawa.

  • Who are AgaPharm's competitors?

    Competitors of AgaPharm include Aerie, Biolog, PPD, Molmed, Bloomage BioTech and 12 more.

Compare AgaPharm to Competitors

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Plexus Ventures Logo
Plexus Ventures

The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies

Hemarina Logo
Hemarina

Hemarina is a privately held biotechnology company focused on the research and development of oxygen-carriers for medical and industrial applications. Hemarina's approach to the development of oxygen transport agents is based on the observation of marine invertebrate colonizing extreme environments and the study of their respiratory adaptations. Hemarina's lead product, Hemarina M-101, is designed to deliver oxygen effectively and efficiently to cells, tissues, organs at risk of oxygen deprivation. Hemarina has already passed a panel of strong proof of concepts obtained during in-vitro and pre-clinical trials.

D
Dr. Alex Waldrop

Dr. Alex Waldrop has developed AcriGlow-301TM to detect the presence of hydrogen peroxide by chemilumniescence for medical and environmental purposes. The European patent has issued for this chemiluminescent technology developed with co-inventor Dr. Calvin Vary of MMCRI (Maine Medical Center Research Institute). Used as a detection system, the process can be adapted to detect a wide variety of substances. Developed with support of MMCRI, Jane Havey of Capricorn Products and the Maine Center for Innovation and Biotechnology (CIBT, the predecessor to MTI), Dr Waldrop hopes to license the technology to clients in the fields of bio-technology and environmental detection. Various companies in the United States, in Japan and in Spain have used the product on a trial basis. The U.S. patent is still pending. This technology has been applied to antibody-based diagnostics.

Bio-Link Logo
Bio-Link

Bio-Link is a National Advanced Technological Education (ATE) Center for Biotechnology that originated in late 1998 with a grant from the National Science Foundation. The ATE program was created to improve and expand educational programs that prepare skilled technicians to work in the high-tech fields that drive the U.S. economy. Bio-Link enhances and expands biotechnology education programs by providing professional development for instructors, by improving curriculum, by making use of technologies and by creating a system that promotes the sharing of information. The Bio-Link National Center is at City College of San Francisco with office space at the University of California San Francisco. Regional Bio-Link Centers across the country are located in Seattle, WA; San Diego, CA; San Francisco, CA; Austin, TX; Madison, WI; Graham, NC; and Portsmouth, NH. The regional centers develop relations with local industry and educational institutions including community colleges, baccalaureate institutions, and high schools. In addition, each regional center spearheads a different element of the program. Bio-Link is supporting a cadre of well-trained instructors and is increasing the number and quality of biotechnology programs for students. Bio-Link aiming to bring a range of underrepresented students to biotechnology who have the knowledge and skills essential to the field as well as the ability to continue with more advanced education in math, science and engineering. At a press conference, on October 15th, 1998, at City College of San Francisco (CCSF), Chancellor Philip R. Day, Jr. stated, "Bio-Link represents a opportunity for community colleges to take a lead in technical training and retraining for the skilled biotechnology workforce of the twenty-first century."nnDr. Elaine Johnson, Director of the National Center and faculty member of CCSF remarked, "In making this award, NSF recognizes both the importance of creating a high performance technical workforce for a competitive global economy and the critical role community and technical colleges play in the education of technicians."

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.